Juventus Therapeutics

Juventus Therapeutics

Juventas Therapeutics is a biotechnology company founded in 2007 that is headquartered in Cleveland, Ohio developing a pipeline of regenerative therapies to treat life-threatening diseases.

Juventas Therapeutics is a biotechnology company developing non-viral gene therapies capable of activating natural processes within the body for healing and repair. The company was founded by Rahul Aras in 2007 and is headquartered in Cleveland, Ohio.

Products
JVS-100

Their first therapeutic product candidate JVS-100 is a non-viral gene therapy expressing a signalling protein that can recruit naturally occurring stem cells and promote tissue repair in a broad range of disease states. Juventas is currently completing a Phase 2b study with JVS-100 in patients with advanced peripheral artery disease.

Funding
Seed

On September 30, 2008 Juventus Therapeutics completed a seed funding round with $300,000 in funding from JumpStart Inc.

Series A

On October 23, 2008 Juventus Therapeutics completed a series A funding round with $7.7 million in funding from Triathlon Medical Venture Partners and Early Stage Partners.

Series B

On July 16, 2012 Juventus Therapeutics completed their series B funding round with $22.2 million in funding from Triathlon Medical Venture Partners (lead investor), New Science Ventures (lead investor), Takeda Ventures, Reservoir Venture Partners, North Coast Angel Fund, New Science Ventures, Fletcher Spaght, and Early Stage Partners.

Timeline

July 16, 2012
Juventus Therapeutics raises a $22,200,000 series B round from Global Cardiovascular Innovation Center, New Science Ventures, Takeda Ventures, Early Stage Partners, Reservoir Venture Partners, Tri-State Growth Fund, Triathlon Medical Venture Partners, Venture Investors, Fletcher Spaght Ventures and Glengary Ventures.
2007
Juventus Therapeutics was founded by Rahul Aras and Marc Penn.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Juventus Therapeutics Series B round
22,200,000
July 16, 2012
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Ben Chlebina

Employee

Joseph Pastore

Senior Vice President, Clinical Product Development

Mathew Pollman

Chief Medical Officer

Michael Fitzgerald

Vice President, Clinical Operations

Rahul Aras

Employee

Rahul Aras

Co-Founder, President, & CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.